Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Mosaicism
- Types of mosaicism
- Gonadal (germ cell) mosaicism
- Albright Hereditary Osteodystrophy (AHO)
- AHO case study
- Disorders linked to germline mosaicism
- Chromosomal mosaicism
- Pallister-Killian syndrome
- Prenatal chromosomal mosaicism
- Fetal-placental and confined placental mosaicism
- Prenatal diagnosis and chromosomal mosaicism
- Mosaicism in skin disorders
- Lines of Blaschko
- Incontinentia Pigmenti
- Neurofibromatosis Type 1 and Type 2
- Mosaicism in Neurofibromatosis Type 1
- Mosaicism in Neurofibromatosis Type 2
- Identifying NF2 variants
- Mosaicism and overgrowth disorders
- Segmental overgrowth disorders
- PI3K-AKT-mTOR signalling pathway
- PIK3CA segmental overgrowth syndromes (PROS)
- Generalised vs. localised overgrowth disorders
- Hemihypertrophy/hyperplasia/lateralised overgowth
- Beckwith-Wiedemann syndrome: clinical features
- Molecular testing for BWS
- The spectrum of BWS/ILO
- Summary
- Acknowledgements and further reading
Topics Covered
- Definition of mosaicism and chimerism
- Types of mosaicism: somatic, gonadal, combined
- Chromosomal disease and mosaicism
- Mosaic skin disorders
- Mosaicism and overgrowth disorders
Links
Series:
Categories:
Talk Citation
Maher, E. (2020, July 30). Mosaicism [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 23, 2024, from https://doi.org/10.69645/VDXT8084.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Eamonn Maher has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Series: Introduction to Human Genetics and Genomics
Transcript
Please wait while the transcript is being prepared...
0:00
My name is Eamonn Maher,
I'm a Professor of Medical Genetics and Genomic Medicine
and Honorary Consultant in Clinical Genetics in
the Department of Medical Genetics at
the University of Cambridge and Cambridge University Hospitals NHS Trust.
I'd like to speak about Mosaicism.
0:18
An individual with a genetic alteration in some of
their cells is mosaic for the relevant genetic alteration.
Some mosaicism arises after fertilisation
and should be distinguished from chimerism which is extremely rare,
the condition in which there are
two genetically distinct cell populations from two different individuals.
For example, if two embryos fuse,
this would result in a chimera.
Mosaicism has long been recognised in specific situations.
For example, as we had in the lecture on X-linked inheritance,
the random X chromosome inactivation that occurs in
normal females means that they can be considered
mosaic as they have two cell populations that
differ according to which X chromosome is silenced.
As we'll see later, this can be of medical significance if
one X chromosome carries a pathogenic variant in an X-linked dominant disease gene.
When cytogeneticists undertake routine analysis for chromosomal abnormalities,
they will look at multiple cells.
Mosaicism for chromosomal disorders such as Turner syndrome,
also known as 45,X,
has long been recognised.
Indeed, if chromosomal mosaicism is
suspected then the cytogeneticists will greatly increase
the number of cells analysed so that lower levels of mosaicism might be detected.
Mosaicism for single gene disorders also occurs,
but until relatively recently has been under diagnosed.
However, with the advent of next-generation sequencing techniques or
other specialist techniques that have been developed to detect
low levels of mosaicism for single gene mutations,
the frequency of recognised cases of mosaicism in many disorders has
increased, because these new techniques are more
sensitive than the conventional Sanger sequencing,
which had previously been used for routine diagnosis for most monogenic disorders.
As we will see, the clinical consequences of mosaicism are very variable.
But in general, an individual who is mosaic for a disorder will have
a milder phenotype than an individual who
carries the genetic alteration in all of their cells.
However, there are some mosaic disorders that cause a severe clinical phenotype.
In these cases, non-mosaic individuals are not seen,
and presumably the non-mosaic cases are not viable.